Captopril-associated cholestasis complicating the management of pancreatic cancer.
Cholestatic jaundice is a rare complication associated with the use of the angiotensin -converting enzyme inhibitor captopril. The severity of the disease may range from cholestasis on liver histology to overt fulminant hepatic failure. This diagnosis is seldom considered in patients with pancreatic or biliary tract malignancy. We present a patient with unresectable adenocarcinoma of the pancreas whose jaundice decreased slowly over many weeks despite establishment of adequate endoscopic biliary drainage. The presence of captopril-associated cholestasis confounded confirmation of adequate biliary drainage. The absence of observed hepatic bile secretion at duodenoscopy, as seen in this patient, is a previously unreported endoscopic feature of this syndrome.
H. Lee Moffitt Cancer Center and Research Institute and the University of South Florida, 12902 Magnolia Drive, Tampa FL 33612-9497, USA.
M A
MA
Kocab
D
D
Coppola
S
S
Hiotis
R C
RC
Karl
J S
JS
Barthel
D000230:Adenocarcinoma / Q000453:epidemiology / Q000601:surgery*; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D002216:Captopril / Q000009:adverse effects* / Q000627:therapeutic use; D002779:Cholestasis / Q000139:chemically induced* / Q000453:epidemiology / Q000209:etiology; D015897:Comorbidity; D003327:Coronary Disease / Q000188:drug therapy* / Q000453:epidemiology; D004322:Drainage / Q000379:methods; D004724:Endoscopy / Q000379:methods*; D006801:Humans; D008297:Male; D010190:Pancreatic Neoplasms / Q000453:epidemiology / Q000601:surgery*; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril